- Have any questions?
- info@mpncancerconnection.org
Understanding the JAK2 Mutation
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
August 28, 2016
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
September 20, 2016Understanding the JAK2 Mutation
THE STORY OF JAK2
Four teams race to find the mysterious cause of a group of blood cancers.
JAK2 MUTATIONS AT A GLANCE
- Involved in: blood cancers and disorders including polycythemia vera, primary myelofibrosis, thrombocythemia, leukemia.
- Testing requires: a blood draw. Bone marrow samples occasionally used.
- Prognosis: Patients with a JAK2 mutation have a lower survival rate and higher rate of blood clots when compared to patients with a CALR mutation.
- Treatment: Ruxolitinib may improve quality of life in patients with a JAK2 mutation.
This Gene is also known as: JTK10, THCYT3
Click the link below for the complete article…
[contentcards url=”https://www.cureforward.com/stories/gene-stories/jak2/” target=”_blank”]
